1. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
- Author
-
Prasad, Sandip M., Huang, William C., Shore, Neal D., Hu, Brian, Bjurlin, Marc, Brown, Gordon, Genov, Pencho, Shishkov, Dimitar, Khuskivadze, Alexandre, Ganev, Tosho, Marchev, Dobri, Orlov, Igor, Kopyltsov, Evgeny, Zubarev, Vadim, Nosov, Alexander, Komlev, Dmitrii, Burger, Brent, Raju, Sunil, Meads, Andrew, and Schoenberg, Mark
- Subjects
BLADDER cancer ,TRANSURETHRAL resection of bladder ,CLINICAL trials ,NON-muscle invasive bladder cancer - Abstract
Purpose: Low-grade intermediate-risk nonmuscle-invasive bladder cancer is a chronic illness commonly treated by repetitive transurethral resection of bladder tumor. We compared the efficacy and safety of intravesical chemoablation with UGN-102 (a reverse thermal gel containing mitomycin), with or without subsequent transurethral resection of bladder tumor, to transurethral resection of bladder tumor alone in patients with low-grade intermediate-risk nonmuscle-invasive bladder cancer. Materials and Methods: This prospective, randomized, phase 3 trial recruited patients with new or recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer to receive initial treatment with either UGN-102 on weeks or transurethral resection of bladder tumor. Patients were followed quarterly by endoscopy, cytology, and for-cause biopsy. The primary end point was disease-free survival. All patients were followed for adverse events. Results: Trial enrollment was halted by the sponsor to pursue an alternative development strategy after 282 of a planned 632 patients were randomized to UGN-102 subsequent transurethral resection of bladder tumor (n[142) or transurethral resection of bladder tumor monotherapy (n[140), rendering the trial underpowered to perform hypothesis testing. Patients were predominantly male and 65 years of age. Tumor-free complete response 3 months after initial treatment was achieved by 92 patients (65%) who received UGN-102 and 89 patients (64%) treated by transurethral resection of bladder tumor. The estimated probability of disease-free survival 15 months after randomization was 72% for UGN-102 transurethral resection of bladder tumor and 50% for transurethral resection of bladder tumor (hazard ratio 0.45). The most common adverse events (incidence 10%) in the UGN-102 group were dysuria, micturition urgency, nocturia, and pollakiuria. Conclusions: Primary, nonsurgical chemoablation with UGN-102 for the management of low-grade intermediate-risk nonmuscle-invasive bladder cancer offers a potential therapeutic alternative to immediate transurethral resection of bladder tumor monotherapy and warrants further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF